Cargando…
Cardiovascular drugs and COVID‐19 clinical outcomes: A living systematic review and meta‐analysis
AIMS: The aim of this study was to continually evaluate the association between cardiovascular drug exposure and COVID‐19 clinical outcomes (susceptibility to infection, disease severity, hospitalization, hospitalization length, and all‐cause mortality) in patients at risk of/with confirmed COVID‐19...
Autores principales: | Asiimwe, Innocent G., Pushpakom, Sudeep, Turner, Richard M., Kolamunnage‐Dona, Ruwanthi, Jorgensen, Andrea L., Pirmohamed, Munir |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8239929/ https://www.ncbi.nlm.nih.gov/pubmed/34101232 http://dx.doi.org/10.1111/bcp.14927 |
Ejemplares similares
-
Cardiovascular drugs and COVID‐19 clinical outcomes: a systematic review and meta‐analysis of randomized controlled trials
por: Asiimwe, Innocent G., et al.
Publicado: (2022) -
Warfarin dosing algorithms: A systematic review
por: Asiimwe, Innocent G., et al.
Publicado: (2020) -
Drug–Drug–Gene Interactions in Cardiovascular Medicine
por: Asiimwe, Innocent G, et al.
Publicado: (2022) -
TAILoR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency Virus [HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduction of Insulin Resistance in HIV-positive Individuals on Combination Antiretroviral Therapy
por: Pushpakom, Sudeep, et al.
Publicado: (2020) -
Telmisartan and Insulin Resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIV-positive individuals on combination antiretroviral therapy
por: Pushpakom, Sudeep P, et al.
Publicado: (2015)